A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

被引：19

作者：

Filippatos, Theodosios D. ^{[1
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 2012年 / 26卷 / 03期

关键词：

Fenofibric acid; Fibrate; Statin; Simvastatin; Atorvastatin; Rosuvastatin; Triglycerides; High-density lipoprotein cholesterol; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; TYPE-2; DIABETES-MELLITUS; FIBRATE-INDUCED INCREASE; MODERATE-DOSE STATIN; PAN-EUROPEAN SURVEY; METABOLIC SYNDROME; MIXED DYSLIPIDEMIA; OBESE-PATIENTS; PHOSPHOLIPASE A(2);

D O I：

10.1007/s10557-012-6394-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fibrates activate peroxisome proliferator activated receptor alpha and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

引用

页码：245 / 255

页数：11

共 90 条

[1]

Agouridis AP, 2010, CURR PHARM DESIGN, V16, P3401, DOI 10.2174/138161210793563464

[2]

Agouridis AP, 2011, EXPERT REV CARDIOVAS, V9, P355, DOI [10.1586/ERC.11.4, 10.1586/erc.11.4]

[3] Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels [J].

Ai, Masumi ;

Otokozawa, Seiko ;

Asztalos, Bela F. ;

Nakajima, Katsuyuki ;

Stein, Evan ;

Jones, Peter H. ;

Schaefer, Ernst J. f .

AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (03) :315-318

[4]

Alagona P, 2010, VASC HEALTH RISK MAN, V6, P351

[5] Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol [J].

Alsheikh-Ali, Alawi A. ;

Lin, Jen-Liang ;

Abourjaily, Paul ;

Ahearn, Dineli ;

Kuvin, Jeffrey T. ;

Karas, Richard H. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (10) :1499-1501

[6]

[Anonymous], 2009, TRIL

[7] Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].

Armitage, Jane ;

Bowman, Louise ;

Wallendszus, Karl ;

Bulbulia, Richard ;

Rahimi, Kazem ;

Haynes, Richard ;

Parish, Sarah ;

Peto, Richard ;

Collins, Rory ;

Meade, T. ;

Sleight, P. ;

Collins, R. ;

Armitage, J. ;

Bowman, L. ;

Parish, S. ;

Peto, R. ;

Barton, J. ;

Bray, C. ;

Wincott, E. ;

Dayanandan, R. ;

Clarke, R. ;

Graham, I. ;

Simpson, D. ;

Warlow, C. ;

Wilken, D. ;

Tobert, J. ;

Mushner, T. ;

Doll, R. ;

Wilhelmsen, L. ;

Fox, K. ;

Hill, C. ;

Sandercock, P. ;

Webster, J. ;

Henderson, J. ;

Nixon, A. ;

Lackie, S. ;

Thompson, J. ;

Brown, M. ;

Blackwood, S. ;

Morgan, M. ;

Rhoden, W. ;

Saeed, B. ;

Houghton, M. ;

Nicholson, A. ;

Simpson, C. ;

Hoburn, B. ;

Cooper, I. ;

Gallivan, A. ;

Pickerell, E. ;

Hancock, J. .

LANCET, 2010, 376 (9753) :1658-1669

[8] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[9] The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia [J].

Bays, Harold E. ;

Roth, Eli M. ;

McKenney, James M. ;

Kelly, Maureen T. ;

Thakker, Kamlesh M. ;

Setze, Carolyn M. ;

Obermeyer, Katie ;

Sleep, Darryl J. .

DIABETES CARE, 2010, 33 (09) :2113-2116

[10] Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia [J].

Bays, Harold E. ;

Jones, Peter H. ;

Mohiuddin, Syed M. ;

Kelly, Maureen T. ;

Sun, Hsiaoming ;

Setze, Carolyn M. ;

Buttler, Susan M. ;

Sleep, Darryl J. ;

Stolzenbach, James C. .

JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (06) :426-435

← 1 2 3 4 5 6 7 8 9 →